BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19013786)

  • 1. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging targeted therapies for breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents on the horizon for cancer therapy.
    Ma WW; Adjei AA
    CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents and future directions for refractory breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging targeted therapies for metastatic breast cancer.
    Perez EA; Spano JP
    Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy of metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
    Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for breast cancer.
    Tookman L; Roylance R
    Br Med Bull; 2010; 96():111-29. PubMed ID: 20870669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in early-stage breast cancer: achievements and promises.
    Sledge GW; Jotwani AC; Mina L
    Surg Oncol Clin N Am; 2010 Jul; 19(3):669-79. PubMed ID: 20620934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer: novel therapies and new directions.
    Pal SK; Mortimer J
    Maturitas; 2009 Aug; 63(4):269-74. PubMed ID: 19632796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
    Chinnaiyan P; Allen GW; Harari PM
    Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.